PIM KINASES INHIBITORS AND PYRIMIDINE-BASED ANTICANCER AGENTS | ||
| Al-Azhar Journal of Pharmaceutical Sciences | ||
| Volume 67, Issue 1, March and April 2023, Pages 68-83 PDF (638.38 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ajps.2023.311247 | ||
| Authors | ||
| ibrahim issa* ; Ahmed Hammam; Helmy Sakr; Rezk Ayyad | ||
| Department of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt | ||
| Abstract | ||
| Human phosphatidyl inositol mannoside kinases (Pim kinases) are important biological target for discovery of new anticancer agents. In addition, Pyrimidines have a good contribution as building blocks of many anticancer agents. Hence, a literature survey about Pim kinases inhibitors and pyrimidine-based anticancer agents have been achieved. In this survey, we introduced Pim kinase inhibitors under clinical assessment including imidazo[1,2-b]pyridazines, isatins, thiazolidine-2,4-diones, pyridinamines, and diaminopyrazoles. In addition, Pim kinase inhibitors under development were presented. These compounds include pyridine-quinolines, benzimidazoles indoles, cyano pyridines, pyridothieno[3,2-d]pyrimidin-4-ones, oxadiazole, and 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones. Furthermore, different pyrimidine-based anticancer agents have been discussed. | ||
| Keywords | ||
| Pim kinases inhibitors; Pyrimidine; Anti-cancer agents | ||
|
Statistics Article View: 372 PDF Download: 527 |
||
